Clinical trials: End-Stage Heart Failure
End Stage Renal Disease, Myocardial Microvascular Disease
Myocardial Microvascular Disease in ESRD
Cardiovascular diseases are the leading cause of mortality in patients with end stage renal disease (ESRD). They often have myocardial ischemia (a major predictor of mortality) on non invasive testing (Stress echocardiography…
- Trial name
- MICROCARD (NCT01291771)
- Testing
- Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
End Stage Renal Disease / Hemodialysis
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
End stage renal disease (ESRD) patients exhibit an extraordinarily high annual mortality. Cardiovascular (CV) causes account for almost half of all-cause mortality.
- Trial name
- MiREnDa (NCT01691053)
- Testing
- Spironolactone
- Where
- 3 sites in Germany
- Volunteers
- 118 people
- Sponsor
- Wuerzburg University Hospital
Seriously Ill Patients, Cancer
Goals of Care Conversations Study
The long term goal is to improve quality of care in Veterans with serious illnesses by aligning medical care with Veterans' goals and values.
- Conditions
- Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease
- Trial name
- LSTDI (NCT05001009)
- Testing
- Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement
- Where
- 3 sites in United States
- Volunteers
- 2,859 people
- Sponsor
- VA Office of Research and Development
End-Stage Renal Disease
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- SPin-D (NCT02285920)
- Testing
- Spironolactone
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Pennsylvania
Haemodialysis Complication, Major Adverse Cardiac Events
Novel Cardiovascular Biomarkers in Patients With Kidney Disease
Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as they should. End-stage kidney failure (ESKD) is the final, irreparable stage of chronic kidney disease (CKD), where kidney function…
- Trial name
- CBKD (NCT06037759)
- Testing
- Cardiac Biomarkers, Lipidomics, Proteomics
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
End-stage Heart Failure
Mechanical Circulatory Support Korea Post Market Surveillance Study (PMS)
Medtronic is sponsoring this Mechanical Circulatory Support (MCS) Korea Post-Market Surveillance (PMS) to evaluate the safety and performance of the HeartWare Ventricular Assist Device System (HVAD® System) when used in routine…
- Trial name
- NCT04543747
- Testing
- HeartWare Ventricular Assist Device
- Where
- 2 sites in South Korea
- Volunteers
- 77 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Orthotopic Heart Transplantation, Graft Failure
Terminal Graft Failure
One of the risks associated with heart transplantation is failure of the graft. A graft is where the new heart is attached to the original vessels in the body.
- Trial name
- NCT00208884
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Emory University
Ventricular Tachycardia, End-stage Heart Failure
Ventricular Tachycardia Ablation in LVAD Patients
The CHANNELED-Registry is a multicenter retrospective study to (1) systematically assess the mechanism and origin of ventricular tachycardia in patients with end-stage heart failure carrying an left ventricular assist device…
- Conditions
- Ventricular Tachycardia, End-stage Heart Failure, Ventricular Arrythmia, LVAD (Left Ventricular Assist Device)
- Trial name
- CHANNELED (NCT06063811)
- Testing
- Ablation
- Volunteers
- 50 people
- Sponsor
- Universitätsklinikum Köln
Atrial Fibrillation, End Stage Renal Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
- Trial name
- RENAL-AF (NCT02942407)
- Testing
- apixaban, warfarin
- Where
- 58 sites in United States
- Volunteers
- 154 people
- Sponsor
- Christopher Granger, MD
End-stage Heart Failure, Cardiomyopathies
Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps
Left Ventricular Assist Device (LVAD) therapy has become a well-established treatment option for endstage heart-failure either as a bridge to transplant (BTT) or destination therapy (DT).
- Conditions
- End-stage Heart Failure, Cardiomyopathies, Mechanical Circulatory Support
- Trial name
- HM3_Snoopy (NCT04641416)
- Testing
- Routinely performed echo, ECG and hemodynamic monitoring
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Thomas Schlöglhofer, PhD, MSc
Heart Failure, Systolic, Renal Disease, End Stage
Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease
Interleukin-1 blockade for the treatment of heart failure in patients with advanced chronic kidney disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a Phase 2, single-arm trial designed to…
- Conditions
- Heart Failure, Systolic, Renal Disease, End Stage, Chronic Kidney Diseases
- Trial name
- E-HART (NCT03062176)
- Testing
- Anakinra
- Sponsor
- Virginia Commonwealth University
Heart Failure, Atrial Fibrillation
Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart Transplantation
CASTLE-HTx will determine if AF ablation has beneficial effects on mortality in patients with end stage HF who are eligible for HTx
- Trial name
- CASTLE-HTx (NCT04649801)
- Testing
- Atrial fibrillation ablation
- Where
- Germany
- Volunteers
- 194 people
- Sponsor
- Heart and Diabetes Center North-Rhine Westfalia
Heart Failure, Heart-assist Devices
PCORI-1310-06998 Trial of a Decision Support Intervention for Patients and Caregivers Offered Destination Therapy Heart Assist Device
The left ventricular assist device (LVAD) is growing rapidly among people dying from end-stage heart failure who are unable to get a heart transplant.
- Trial name
- DECIDE-LVAD (NCT02344576)
- Testing
- DT LVAD Decision Support Intervention
- Where
- 6 sites in United States
- Volunteers
- 445 people
- Sponsor
- University of Colorado, Denver
End-stage Heart Failure
Carmat TAH Early Feasibility Study
Feasibility study of the Carmat TAH as a treatment for transplant-eligible patients in severe, end-stage heart failure.
- Trial name
- NCT04117295
- Testing
- Carmat Total Artificial Heart
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Carmat SAS
End-stage Renal Disease, Left Ventricular Hypertrophy
Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease
Background: Recent data indicate that home nocturnal hemodialysis (8 hours of hemodialysis at home for 5-6 nights per week) may have substantial cardiovascular benefits, including regression of left ventricular (LV) hypertrophy…
- Trial name
- NCT00718848
- Testing
- Incentre nocturnal hemodialysis, Remaining on conventional hemodialysis
- Where
- 2 sites in Canada
- Volunteers
- 67 people
- Sponsor
- Unity Health Toronto
End-stage Heart Failure Awaiting VAD Implantation
COVADIS Pilot Trial: COseal in Ventricular Assist DevIceS
The objective of this controlled, non-randomized, single-center pilot study (CoSeal arm prospective)study is to evaluate the efficacy of the synthetic surgical hydrogel CoSeal® in the prevention of cardiac adhesion formation in…
- Trial name
- COVADIS (NCT01244321)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- German Heart Institute
Cardiogenic Shock, Renal Replacement Therapy
REnal reCOVery After ECMO for Cardiogenic Shock (RECOVECMO)
This retrospective study assesses long term renal outcome in patients having suffered medical or post cardiotomy refractory cardiogenic shock requiring renal replacement therapy (RRT) concomitant with veno-arterial extracorporeal…
- Conditions
- Cardiogenic Shock, Renal Replacement Therapy, Venoarterial Extracorporeal Membrane Oxygenation
- Trial name
- RECOVECMO (NCT05788211)
- Testing
- standard of care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- University Hospital, Bordeaux
End-stage Renal Disease
IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Failure
The objectives of this trial are to determine whether, in critically ill ESKD patients randomization to fluid removal guided by lung and inferior vena cava ultrasound, compared to standard care, leads to Improved pulmonary…
- Trial name
- NCT06373575
- Testing
- Lung and inferior vena cava ultrasound guidance, Conventional protocol guidance
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
End-Stage Renal Disease
Vitamin D3 Supplementation in Dialysis Patients
Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide.
- Trial name
- NCT01312714
- Testing
- Cholecalciferol
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Regional Hospital Holstebro
Heart Failure, Heart Failure At NYHA Stage III or IV
IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure
This clinical trial investigates the safety, feasibility, and therapeutic potential of a combined approach using HiCM-188 cardiomyocyte injection delivered intramyocardially alongside either LVAD implantation or CABG surgery in…
- Trial name
- NCT06866600
- Testing
- low dose CABG+iPSC-CMs, High dose CABG/LVAD+iPSC-CMs, CABG/LVAD+Saline
- Where
- China
- Volunteers
- 40 people
- Sponsor
- HELP Therapeutics Co., Ltd.